Zanidatamab Shows Durable Responses With Longer Follow-up in Pretreated HER2+ Biliary Tract Cancer
Cabazitaxel/Abiraterone Combination Prolongs PFS vs Abiraterone in mCRPC
Pembrolizumab Plus Sacituzumab Govitecan Shows Nonsignificant Trend Toward Improved PFS in HR+ Breast Cancer
Virtual and In-Person Delivery of Palliative Care Confers Equivalent QOL Benefit in Advanced Lung Cancer
2 Commerce Drive
Cranbury, NJ 08512